source
- J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million i…
- J&J invests $785M in Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson has agreed to pay $785 million up front to Sail Biomedicines, including a $465 million equity infusion and up to $140 million in milestone payments. The agreement also gives J&J a…